AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
Five presentations at the
AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies
LAUSANNE,
Prof.
Translational drug discovery in PD/LBD Phase I-III – Recent updates
Date: Thu,
Panelist: Forum discussion with Prof. Johannes Streffer (
ACI-12589 alpha-synuclein imaging agent
Discovery of [18F] ACI-12589, a novel and promising PET-tracer for alpha-synuclein
Date: Fri,
Presenter: Oral presentation by
Initial scans using [18F] ACI-12589, a novel PET-tracer for alpha-synuclein
Date: Fri,
Presenter: Oral presentation by Prof.
ACI-24 anti-Abeta vaccine
An optimized amyloid beta (abeta) vaccine that safely drives immunity to the key pathological species of Alzheimer’s disease (AD)
Date: Fri,
Presenter: Oral presentation by
TDP-43 therapeutics & diagnostics
TDP-43 immunotherapy decreases neuropathology and confers neuroprotection through microglial engagement in mouse models of ALS/FTD
Date: Fri,
Presenter: Oral presentation by
TDP-43 and C9ORF72-related diseases 2: optimization of PET Tracers for TDP-43 proteinopathies
Date: Available online from
Presenter: On demand presentation by Tamara Seredenina, Ph.D. (
About
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP and RU. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, and NO.
For further information, please contact:
| Media Relations Phone: +41 21 345 91 34 Email: saoyuth.nidh@acimmune.com |
Investor Relations Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com |
LaVoieHealthScience Phone: +1 609 516 5761 Email: slewis@lavoiehealthscience.com |
U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA